Trials benefit from acronyms
Naming randomized trials with acronyms may enhance citation rate after publication, according to a study published in the July 6 issue of the New England Journal of Medicine. Acronym-named randomized trials published between 1953 and 2003 were cited at twice the rate of trials not named with acronyms. Trial acronyms may have subliminal influences "since specific acronyms could invoke subconscious value-laden associations that might enhance positive perceptions of the studies they name," study authors note...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.